An untreatable Ebola-like virus — which kills up to nine in 10 people it infects — is currently spreading in Africa.
Marburg, one of the deadliest pathogens ever discovered, has already killed nine in Equatorial Guinea.
Two suspected cases have since been spotted in neighbouring Cameroon, sparking fears that the virus may be spreading under the radar.
The World Health Organization has deployed teams to Equatorial Guinea, who are working at ‘full steam’ to ‘save lives and halt the virus as soon as possible’.
But what is Marburg? How does it spread? And are there any treatments to stop the spread of infection? Here, we answer all your questions.
How deadly is Marburg?
Marburg is one of the deadliest pathogens known to man.
The WHO says it has a case-fatality ratio (CFR) of up to 88 per cent.
But experts estimate that it probably sits closer to the 50 per cent mark, similar to its cousin Ebola — another member of the filoviridae family.
That means that out of every 100 people confirmed to be infected with Marburg, half would be expected to die.
Scientists don’t, however, know the infection-fatality rate, which measures everyone who gets infected — not just cases that test positive.
For comparison, Covid had a CFR of around 3 per cent when it burst onto the scene.
Is there a vaccine?
No vaccines are currently approved to treat the virus.
The WHO convened an urgent meeting on Monday over the rising cases, calling in experts from around the world.
Members of the Marburg virus vaccine consortium (MARVAC) — speaking to the WHO — said it could take months for effective vaccines and therapeutics to become available, as manufacturers would need to gather materials and perform trials.
Experts identified 28 experimental vaccine candidates that could be effective against the virus — most of which were developed to combat Ebola.
Five were highlighted in particular as vaccines to be explored.
Three vaccine developers — Janssen Pharmaceuticals, Public Health Vaccines and the Sabin Vaccine Institute — said they may be able to make doses available to test in the current outbreak.
The vaccines from Janssen and Sabin have already gone through phase one clinical trials. However, none of the vaccines are available in large quantities.
Public Health Vaccines’ jab was also recently found to protect against the virus in monkeys, and the Food and Drug Administration has cleared it for human testing.
What about drugs, have any been proven to work?
As well as there being no vaccines, there are also no treatments approved to treat the virus.
However, the WHO is currently evaluating a range of potential treatments, including blood products, immune therapies and drug therapies.
The UN agency also advises that supportive care such as rehydration and drugs to ease certain symptoms can improve survival chances.
Supportive hospital therapy includes balancing the patient’s fluids and electrolytes, maintaining oxygen levels and blood pressure, replacing lost blood and clotting factors, and treatment for any complicating infections.
According to the Centers for Disease Control and Prevention (CDC), experimental treatments have never been tested on humans.
How far away are therapeutics realistically?
Experts told MailOnline yesterday that it may take multiple outbreaks for enough cases to properly analyze the virus’s effectiveness and ‘years’ before an effective therapeutic becomes available.
Professor Jimmy Whitworth, a professor of international public health at the London School of Hygiene & Tropical Medicine, said: ‘Usually Marburg virus outbreaks develop very quickly, only a few cases are infected, and the outbreak dies down rapidly once control measures are in place.
‘If the current outbreak follows this pattern it will be very challenging to test the effectiveness of candidate vaccines.’
He added: ‘It is likely that any vaccine will need to be tested over several outbreaks before we have a definite answer on whether it works.’
Instead, health officials hope the virus — which spreads via prolonged physical contact — will be contained and controlled before it causes a larger outbreak.
Dr Michael Head, senior research fellow in global health at the University of Southampton, also told MailOnline: ‘There’s no immediate timescale of when we might see a Marburg vaccine.
‘There are many promising candidates, but my best guess is we’re probably some years off seeing a finished product being widely available in high-risk settings.’
How is this outbreak being contained?
Hundreds of people suspected to be infected with the virus have already been quarantined in Equatorial Guinea.
International aid agencies have deployed teams on the ground in Kie Ntem, where all 16 cases so far have been spotted.
The WHO has deployed ‘health emergency experts’ in epidemiology, case management, infection prevention, laboratory and risk communication to support response efforts.
It is also helping to ship laboratory glove tents for sample testing as well as one viral hemorrhagic fever kit.
Neighbouring countries Cameroon and Gabon have restricted movement along their borders over concerns about contagion.
How far has it spread?
In Cameroon, a 16-year-old boy and girl from the commune of Olamze, around two miles from the border, showed signs of the disease.
Neither had recently traveled to Equatorial Guinea.
How bad were previous Marburg clusters and where were they?
Before this outbreak, only 30 cases had been recorded globally from 2007 to 2022.
Angola, in central Africa, faced the largest known outbreak in 2004. It had a 90 per cent fatality rate, with 227 deaths among 252 infected people, according to the Angolan Government.
Last September, Ghana declared the end of a Marburg outbreak which affected the country’s Ashanti, Savannah and Western regions.
Could it reach Britain or the US?
Most outbreaks of Marburg fizzle out after infecting a few people.
For this reason, experts say the chances of it sparking a pandemic are tiny. Yet, it is not impossible.
Professor Whitworth told MailOnline yesterday: ‘Marburg outbreaks are always concerning because of the high case fatality rate and the potential for spreading from person to person by close contact.’
However, the speed at which the outbreak in Equatorial Guinea was spotted by officials may have helped dampen the spread of infection so far, he advised.
He said: ‘This outbreak has occurred in a remote forested area of Equatorial Guinea which limits the potential for spreading fast or affecting many people.
‘It also appears to have been spotted quickly, the number of suspected cases is small and the first death under investigation occurred on January 7, so only about five weeks ago.’
But he added: ‘The outbreak has occurred close to the international borders with Cameroun and Gabon so international co-ordination will be required.
‘So, overall, the risk for Equatorial Guinea and the region is moderate, and the risk of it spreading outside the region is very low.’
What are the tell-tale symptoms?
Symptoms appear abruptly and include severe headaches, fever, diarrhoea, stomach pain and vomiting. They become increasingly severe.
In the early stages of MVD — the disease it causes — it is very difficult to distinguish from other tropical illnesses, such as Ebola, and malaria.
Infected patients become ‘ghost-like’, often developing deep-set eyes and expressionless faces.
This is usually accompanied by bleeding from multiple orifices — including the nose, gums, eyes and vagina.
Like Ebola, even dead bodies can spread the virus to people exposed to its fluids.
How does the virus spread?
Human infections typically start in areas where people have prolonged exposure to mines or caves inhabited by infected fruit bat colonies.
Fruit bats naturally harbour the virus.
It can, however, then spread between humans, through direct contact with the bodily fluids of infected people, surfaces and materials.
Contaminated clothing and bedding is a risk, as are burial ceremonies that involve direct contact with the deceased.
In Equatorial Guinea, the virus was found in samples taken from deceased patients suffering from symptoms including fever, fatigue and blood-stained vomit and diarrhea.
Healthcare workers have been frequently infected while treating Marburg patients.
Gavi, an international organisation promoting vaccine access, says that people in Africa should avoid eating or handling bushmeat.
Is Marburg as contagious as Covid?
Covid took off so quickly because of how it spread — through infectious respiratory particles when they are inhaled, or come into contact with the eyes, nose or mouth.
Marburg, although contagious, is nowhere near as infectious.
As it outbreaks are so sporadic, scientists have never been able to pinpoint its R rate — which epidemiologists use measure a disease’s ability to spread.
R is, in essence, the number of people that one infected person will pass on a virus to, on average.
Ebola, when it swept through West Africa between 2014 and 2016, had an R rate of around 1.5, studies suggest.
Covid, for comparison, has mutated to have a basic R rate even higher than measles (around 15).
Why is it called Marburg and how long have scientists known about it?
Marburg was first recognised in 1967, when outbreaks of hemorrhagic fever occurred simultaneously in laboratories in Marburg and Frankfurt, Germany and in Belgrade, Yugoslavia (now Serbia).
The infections were traced back to three laboratories which received a shared shipment of infected African green monkeys.
There have been eight subsequent outbreaks involving multiple infections, including the current outbreak in Equatorial Guinea and Cameroon.
MVD is normally associated with outbreaks in Angola, the Democratic Republic of the Congo, Kenya, South Africa and Uganda.
SOURCE: dailymail.co.uk
